This week's featured physician executive is James B. Jones, M.D., Pharm.D., as Chief Medical Officer of Cara Therapeutics, Inc.
Here are a few snippets from a recent press release:
SHELTON, Conn., March 30, 2011 /PRNewswire/ -- Cara Therapeutics, Inc. today announced the appointment of James B. Jones, M.D., Pharm.D., to the position of Chief Medical Officer. In this role, Dr. Jones will oversee the ongoing clinical development of Cara's lead drug candidate, CR845, a novel, peripherally-restricted kappa opioid agonist, which is currently in Phase 2 development for treatment of post-operative pain.
Dr. Jones most recently was the Chief Medical Officer at Strativa Pharmaceuticals, a division of Par Pharmaceuticals, Inc. Previously, he was the VP of Clinical Development and Medical Affairs at Xanodyne Pharmaceuticals where he was instrumental in the approval and subsequent launch of Zipsor (diclofenac potassium). Prior to Xanodyne, Dr. Jones was VP of Clinical Development at Alpharma Pharmaceuticals where he was actively involved in the development of EMBEDA (morphine sulfate and naltrexone hydrochloride). Other analgesics/CNS compounds that Dr. Jones has worked on include Lusedra (fospropofol disodium) while at Guilford Pharmaceuticals as well as valdecoxib and parecoxib while at Pharmacia. Dr. Jones received his Doctorate of Medicine degree from the University of Pennsylvania and his Doctorate of Pharmacy from Purdue University.
Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. In addition to CR845, Cara's current pipeline includes near-term clinical development candidates within multiple proprietary classes of peripherally restricted cannabinoids with preclinical analgesic and anti-inflammatory activity. Cara also plans to develop entirely novel classes of analgesics that emerge from its proprietary GPCR DimerScreen technology.